English
Home > Products > CAS NO 923288-90-8

China CAS NO 923288-90-8 Factory

It adheres to the tenet ""Honest, industrious, enterprising, innovative"" to develop new products constantly. It regards customers, success as its own success. Let us develop prosperous future hand in hand for CAS NO 923288-90-8,923288-90-8,Nilotinib API,Nilotinib Hydrochloride Monohydrate, Welcome your enquiry, most effective service will likely be provided with full heart.
CAS NO 923288-90-8, Why we can do these? Because: A, We have been honest and reliable. Our solutions have high quality, attractive price, sufficient supply capacity and perfect service. B, Our geographical position has a big advantage . C, Various types: Welcome your inquiry, It will probably be highly appreciated.

Related Products

Hot Products

  • L-Isoleucine

    L-Isoleucine

    Product Name:L-Isoleucine
    Molecular Formula:C6H13NO2
    Molecular Weight:131.17
    CAS Registry Number:73-32-5
  • Clarithromycin

    Clarithromycin

    Product Name:Clarithromycin
    Molecular Formula:C38H69NO13
    Molecular Weight;747.95
    CAS Registry Number;81103-11-9
  • 2,4-Dichloro-5-fluoropyrimidine

    2,4-Dichloro-5-fluoropyrimidine

    Product Name:2,4-Dichloro-5-fluoropyrimidine
    Molecular Formula:C4HCl2FN2
    Molecular Weight:166.97
    CAS Registry Number:2927-71-1
  • Tetraethylammonium tetrafluoroborate

    Tetraethylammonium tetrafluoroborate

    Product Name:Tetraethylammonium tetrafluoroborate
    Molecular Formula:C8H20BF4N
    Molecular Weight:217.06
    CAS Registry Number:429-06-1
  • Arabinoguanosine

    Arabinoguanosine

    Product Name:Arabinoguanosine
    Molecular Formula:C10H13N5O5
    Molecular Weight:283.24
    CAS Registry Number:38819-10-2
  • 6-Hydroxypurine

    6-Hydroxypurine

    Product Name:6-Hydroxypurine
    Molecular Formula:C5H4N4O
    Molecular Weight:136.11
    CAS Registry Number:68-94-0
  • Related Blog
  • Reviews

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept